Research programme: small molecule therapeutics - Solu Therapeutics
Latest Information Update: 24 Aug 2023
At a glance
- Originator GSK
- Developer GSK; Solu Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Immunological disorders